Tissue Regenix Group (LSE:TRX) EBITDA Margin %: 0.30% (As of Jun. 2025)


What is Tissue Regenix Group EBITDA Margin %?

Tissue Regenix Group LSE:TRX EBITDA Margin % is 0.30% as of Jun. 2025. The stock has 5 warning signs investors should review.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tissue Regenix Group's EBITDA for the six months ended in Jun. 2025 was £0.03 Mil. Tissue Regenix Group's Revenue for the six months ended in Jun. 2025 was £10.17 Mil. Therefore, Tissue Regenix Group's EBITDA margin for the quarter that ended in Jun. 2025 was 0.30%.

Tissue Regenix Group  (LSE:TRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Tissue Regenix Group EBITDA Margin % Related Terms

Tissue Regenix Group EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Tissue Regenix Group's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tissue Regenix Group EBITDA Margin % Chart

Tissue Regenix Group Annual Data
Trend Jan15 Jan16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.97 -17.01 -3.89 -0.08 4.76

Tissue Regenix Group Semi-Annual Data
Jul15 Jan16 Jul16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.86 -2.32 5.80 3.67 0.30

LSE:TRX vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Tissue Regenix Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tissue Regenix Group EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tissue Regenix Group's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Tissue Regenix Group's EBITDA Margin % falls into.


Tissue Regenix Group EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Tissue Regenix Group's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=1.079/22.659
=4.76 %

Tissue Regenix Group's EBITDA Margin % for the quarter that ended in Jun. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Jun. 2025 )/Revenue (Q: Jun. 2025 )
=0.031/10.168
=0.30 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.30% mean?
Tissue Regenix Group (LSE:TRX) has a EBITDA Margin % of 0.30% as of Jun. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tissue Regenix Group and its competitors.
Is Tissue Regenix Group's EBITDA Margin % too high?
Tissue Regenix Group's current EBITDA Margin % is 0.30%.
How does Tissue Regenix Group's EBITDA Margin % compare to VRTX and REGN?
Tissue Regenix Group's EBITDA Margin % of 0.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tissue Regenix Group and its competitors. Tissue Regenix Group's current EBITDA Margin % is 0.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tissue Regenix Group stock overvalued right now?
Tissue Regenix Group (LSE:TRX) has a current EBITDA Margin % of 0.30%. The stock's GF Value™ is £0.87, compared to a current price of £0.07 — trading 91.7% below its estimated fair value. The current EBITDA Margin % is 0.30%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tissue Regenix Group (LSE:TRX), the current EBITDA Margin % is 0.30% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tissue Regenix Group Business Description

Address Lotherton Way, Unit 3, Phoenix Court, Garforth, GBR, LS25 2GY
Tissue Regenix Group PLC is a pioneering medical technology company engaged in the development of regenerative products. The company incorporates dCELL and BioRinse technology, which helps to address complex and varying clinical needs. Its product portfolio includes Biosurgery, Orthopaedics, and Dental. The company has operations around the world, with special emphasis in the United States.